Using the TriNetX records network, adults who underwent catheter ablation for atrial fibrillation between 2018 and 2024 were grouped by prior use of GLP-1 receptor agonists, SGLT2 inhibitors or both, and matched on propensity score. Arrhythmia recurrence after the three-month blanking period did not differ in any of the three comparisons (hazard ratios 1.01 to 1.13). All-cause mortality was lower with the combination than with either drug alone (HR 0.54, 95% CI 0.34 to 0.87 against GLP-1 alone, and HR 0.60, 95% CI 0.39 to 0.93 against SGLT2 alone), on small numbers of deaths and with wide intervals.
Why it is interesting: A mortality difference appears in routine records where the arrhythmia outcome does not, and it rests on small numbers of deaths in an observational comparison.